Challenges of antibody-mediated protection against HIV-1

References

• Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature422(6929), 307–312 (2003).
   PubMed Web of Science ®Google Scholar
• Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA100(7), 4144–4149 (2003).
   PubMed Web of Science ®Google Scholar
• Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med.6(2), 200–206 (2000).
   PubMed Web of Science ®Google Scholar
• Putkonen P, Thorstensson R, Ghavamzadeh L et al. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature352(6334), 436–438 (1991).
   PubMed Web of Science ®Google Scholar
• Emini EA, Schleif WA, Nunberg JH et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature355(6362), 728–730 (1992).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Lewis MG, Stiegler G et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol.73(5), 4009–4018 (1999).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med.6(2), 207–210 (2000).
   PubMed Web of Science ®Google Scholar
• Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med.5(2), 204–210 (1999).
   PubMed Web of Science ®Google Scholar
• Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.J. Virol.75(17), 8340–8347 (2001).
   PubMed Web of Science ®Google Scholar
• Prince AM, Reesink H, Pascual D et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retroviruses7(12), 971–973 (1991).
   PubMed Web of Science ®Google Scholar
• Putkonen P, Thorstensson R, Ghavamzadeh L et al. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature352, 436–438 (1991).
   PubMed Web of Science ®Google Scholar
• Gardner MB, Rosenthal A, Jennings M, Yee JA, Antipa L, Robinson EJ. Passive immunization of rhesus macques against SIV infection and disease. AIDS Res. Hum. Retroviruses11, 843–854 (1995).
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Berardi CJ, Dillard-Telm S et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis.177(5), 1247–1259 (1998).
   PubMed Web of Science ®Google Scholar
• Joag SV, Li Z, Wang C et al. Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus. AIDS Res. Hum. Retroviruses15(4), 391–394 (1999).
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Poignard P, Hunter M et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med.15(8), 951–954 (2009).
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Poignard P et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog.5(5), e1000433 (2009).
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Tehrani DM et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10, directed against the human immunodeficiency virus type 1 (HIV-1) gp41 membrane proximal external region (MPER), protect against SHIVBa-L mucosal challenge. J. Virol.84(3), 1302–1313 (2010).
   PubMed Web of Science ®Google Scholar
• Hofmann-Lehmann R, Rasmussen RA, Vlasak J et al. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J. Med. Primatol.30(4), 190–196 (2001).
   PubMed Web of Science ®Google Scholar
• Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med.5(2), 204–210 (1999).
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Igarashi T, Haigwood N et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol.76(5), 2123–2130 (2002).
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol.4(3), 199–210 (2004).
   PubMed Web of Science ®Google Scholar
• Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J. Virol.75(13), 5721–5729. (2001).
   PubMed Web of Science ®Google Scholar
• Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol.5(3), 233–236 (2004).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu. Rev. Immunol.28, 413–444 (2010).
   PubMed Web of Science ®Google Scholar
• Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol.6(2), 143–155 (2008).
   PubMed Web of Science ®Google Scholar
• Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull.58, 19–42 (2001).
   PubMed Web of Science ®Google Scholar
• Korber B, Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS4(5), 408–417 (2009).
   PubMed Web of Science ®Google Scholar
• Guan Y, Sajadi MM, Kamin-Lewis R et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc. Natl Acad. Sci. USA106(10), 3952–3957 (2009).
   PubMed Web of Science ®Google Scholar
• Liao HX, Levesque MC, Nagel A et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol Methods158(1–2), 171–179 (2009).
   PubMed Web of Science ®Google Scholar
• Scheid JF, Mouquet H, Feldhahn N et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature458(7238), 636–640 (2009).
   PubMed Web of Science ®Google Scholar
• Walker LM, Phogat SK, Chan-Hui PY et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science326(5950), 285–289 (2009).
   PubMed Web of Science ®Google Scholar
• Corti D, Langedijk JP, Hinz A et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One5(1), e8805 (2010).
   PubMed Web of Science ®Google Scholar
• Crooks ET, Moore PL, Richman D et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum. Antibodies14(3–4), 101–113 (2005).
   PubMedGoogle Scholar
• Polonis VR, Brown BK, Rosa Borges A et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology375(2), 315–320 (2008).
   PubMed Web of Science ®Google Scholar
• Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, Trkola A. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS23(13), 1659–1667 (2009).
   PubMed Web of Science ®Google Scholar
• Fenyo EM, Heath A, Dispinseri S et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One4(2), e4505 (2009).
   Google Scholar
• Gomez-Roman VR, Patterson LJ, Venzon D et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol.174(4), 2185–2189 (2005).
   PubMed Web of Science ®Google Scholar
• DeVico A, Fouts T, Lewis GK et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl Acad. Sci. USA104(44), 17477–17482 (2007).
   PubMed Web of Science ®Google Scholar
• Hidajat R, Xiao P, Zhou Q et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol.83(2), 791–801 (2009).
   PubMed Web of Science ®Google Scholar
• Li A, Baba TW, Sodroski J et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retroviruses13(8), 647–656 (1997).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Louder MK, VanCott TC et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol.71(10), 7198–7206 (1997).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Lewis MG, Stiegler G et al. Protection of macaques against pathogenic simian/human immunodefiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol.73, 4009–4018 (1999).
   PubMed Web of Science ®Google Scholar
• Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.J. Virol.75(17), 8340–8347 (2001).
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Igarashi T, Haigwood N et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol.76(5), 2123–2130 (2002).
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature449(7158), 101–104 (2007).
   PubMed Web of Science ®Google Scholar
• Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol.75(24), 12161–12168 (2001).
   PubMed Web of Science ®Google Scholar
• Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS4(5), 388–393 (2009).
   PubMed Web of Science ®Google Scholar
• Xiao P, Zhao J, Patterson LJ et al. Multiple vaccine-elicited non-neutralizing anti-envelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following SHIV89.6P challenge in rhesus macaques. J. Virol. DOI: 10.1128/JVI.00410-10 (2010) (Epub ahead of print).
   Google Scholar
• Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol.178(10), 6596–6603 (2007).
   PubMed Web of Science ®Google Scholar
• Shen R, Drelichman ER, Bimczok D et al. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J. Immunol.184(7), 3648–3655 (2010).
   PubMed Web of Science ®Google Scholar
• Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol.67(1), 53–59 (1993).
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Moody MA, Parks RJ et al. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol.183(4), 2708–2717 (2009).
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Igarashi T, Haigwood NL et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl Acad. Sci. USA100(25), 15131–15136 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrantelli F, Buckley KA, Rasmussen RA et al. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology358(1), 69–78 (2007).
   PubMed Web of Science ®Google Scholar
• Manca N, di Marzo Veronese F, Ho DD, Gallo RC, Sarngadharan MG. Sequential changes in antibody levels to the env and gag antigens in human immunodeficiency virus infected subjects. Eur. J. Epidemiol.3(2), 96–102 (1987).
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med.357(19), 1903–1915 (2007).
   PubMed Web of Science ®Google Scholar
• Vigerust DJ, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol.15(5), 211–218 (2007).
   PubMed Web of Science ®Google Scholar
• Finzi A, Xiang SH, Pacheco B et al. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell.37(5), 656–667 (2010).
   PubMed Web of Science ®Google Scholar
• Pancera M, Majeed S, Ban YE et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl Acad. Sci. USA107(3), 1166–1171 (2010).
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr. Opin Immunol.11(2), 172–179 (1999).
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361(23), 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar